We are a clinical-stage biotechnology company focused on the discovery and development of targeted therapies for skin disorders driven by aberrant activation of the RAS pathway. We are initially focused on the treatment of cutaneous neurofibromas in neurofibromatosis type 1, disfiguring congenital birthmarks (including keratinocytic epidermal nevi and nevus sebaceous), and the prevention of immunosuppressant-mediated squamous cell carcinoma.

We are funded by F-Prime Capital, venBio, and the Children’s Tumor Foundation and have assembled a proven team of experienced drug development professionals and key opinion leaders to develop a “soft” (metabolically labile) topical MEK inhibitor to treat disfiguring RAS-mediated conditions of the skin.